NKGen Biotech (NKGN) Stock Overview
A clinical-stage biotechnology company, develops and commercializes cell therapies for neurodegenerative and oncological diseases based on activated natural killer (NK) cells in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
NKGN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
NKGen Biotech, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.06 |
| 52 Week High | US$0.91 |
| 52 Week Low | US$0.0002 |
| Beta | 0.94 |
| 1 Month Change | 62.16% |
| 3 Month Change | 9,900.00% |
| 1 Year Change | -89.29% |
| 3 Year Change | -99.40% |
| 5 Year Change | n/a |
| Change since IPO | -99.38% |
Recent News & Updates
Recent updates
Shareholder Returns
| NKGN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 20.0% | 0.7% | 1.0% |
| 1Y | -89.3% | 23.7% | 17.2% |
Return vs Industry: NKGN underperformed the US Biotechs industry which returned 20.9% over the past year.
Return vs Market: NKGN underperformed the US Market which returned 16.6% over the past year.
Price Volatility
| NKGN volatility | |
|---|---|
| NKGN Average Weekly Movement | 144.8% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NKGN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: NKGN's weekly volatility has increased from 78% to 145% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 26 | Paul Y. Song | nkgenbiotech.com |
NKGen Biotech, Inc., a clinical-stage biotechnology company, develops and commercializes cell therapies for neurodegenerative and oncological diseases based on activated natural killer (NK) cells in the United States. The company develops SNK01, an autologous NK cell therapy candidate in Phase I/IIa trial for the treatment of neurodegenerative diseases, such as Alzheimer’s and Parkinson's disease; and SNK02, which consists of an allogenic NK cell therapy that has completed Phase 1 trial and a HER2-CAR NK cell therapy candidate in pre-clinical trial to treat refractory solid tumors. It has a strategic partnership with HekaBio K.K., a Japan-based healthcare platform, to develop, conduct clinical trials, obtain regulatory approvals, manufacture, and commercialize the company’s autologous NK cell therapy product candidates for central nervous system and autoimmune conditions in Japan.
NKGen Biotech, Inc. Fundamentals Summary
| NKGN fundamental statistics | |
|---|---|
| Market cap | US$6.22m |
| Earnings (TTM) | -US$44.29m |
| Revenue (TTM) | n/a |
Is NKGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NKGN income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$44.29m |
| Earnings | -US$44.29m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.36 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -75.1% |
How did NKGN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/06 03:44 |
| End of Day Share Price | 2026/01/06 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
NKGen Biotech, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.